HomeONC • NASDAQ
add
Beigene Ltd
Previous close
$271.80
Day range
$240.00 - $258.96
Year range
$172.67 - $287.88
Market cap
25.56B USD
Avg Volume
448.91K
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.19B | 84.84% |
Operating expense | 1.09B | 19.51% |
Net income | -139.70M | 58.27% |
Net profit margin | -11.75 | 77.43% |
Earnings per share | -0.80 | -196.59% |
EBITDA | -33.25M | 90.73% |
Effective tax rate | -112.84% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.63B | -17.16% |
Total assets | 5.92B | 1.99% |
Total liabilities | 2.59B | 14.14% |
Total equity | 3.33B | — |
Shares outstanding | 106.72M | — |
Price to book | 8.71 | — |
Return on assets | -3.26% | — |
Return on capital | -4.29% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -139.70M | 58.27% |
Cash from operations | 111.61M | 128.21% |
Cash from investing | -247.31M | 26.86% |
Cash from financing | 30.05M | -92.11% |
Net change in cash | -155.64M | 57.59% |
Free cash flow | 434.97M | 505.95% |
About
BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia. BeiGene has a large presence in the Chinese market. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November, 2024 the company announced its intention to rebrand as BeOne Medicines. Wikipedia
Founded
Oct 28, 2010
Website
Employees
11,000
